Liquidia (NASDAQ:LQDA) Downgraded by Zacks Research to Hold

Liquidia (NASDAQ:LQDA) was downgraded by Zacks Research from a “strong-buy” rating to a “hold” rating in a research report issued to clients and investors on Thursday,Zacks.com reports.

A number of other equities research analysts have also weighed in on LQDA. Needham & Company LLC raised their price objective on Liquidia from $70.00 to $110.00 and gave the company a “buy” rating in a research note on Wednesday. BTIG Research increased their target price on Liquidia from $109.00 to $111.00 and gave the company a “buy” rating in a research note on Wednesday. Royal Bank Of Canada set a $130.00 price target on shares of Liquidia in a research report on Friday, July 24th. Lifesci Capital lowered shares of Liquidia from an “outperform” rating to a “hold” rating and set a $90.00 price target for the company. in a research note on Wednesday. Finally, Raymond James Financial reaffirmed a “strong-buy” rating and issued a $106.00 price target on shares of Liquidia in a report on Thursday. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, three have given a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $98.08.

Liquidia Trading Up 3.2%

Shares of LQDA stock opened at $74.44 on Thursday. The stock has a market cap of $6.62 billion, a price-to-earnings ratio of 54.34 and a beta of 0.58. The company has a quick ratio of 2.03, a current ratio of 2.31 and a debt-to-equity ratio of 0.63. Liquidia has a fifty-two week low of $21.15 and a fifty-two week high of $93.61. The firm’s 50 day moving average price is $78.67 and its two-hundred day moving average price is $55.13.

Liquidia (NASDAQ:LQDA) last issued its earnings results on Wednesday, August 12th. The company reported $0.74 earnings per share for the quarter, missing the consensus estimate of $0.76 by ($0.02). The company had revenue of $171.68 million during the quarter, compared to analysts’ expectations of $168.48 million. Liquidia had a return on equity of 149.65% and a net margin of 30.74%.Liquidia’s quarterly revenue was up 1842.1% on a year-over-year basis. During the same period in the previous year, the company earned ($0.49) EPS. On average, analysts anticipate that Liquidia will post 2.74 EPS for the current year.

Insider Buying and Selling at Liquidia

In other Liquidia news, insider Sanjeev Khindri sold 1,185 shares of the business’s stock in a transaction on Monday, July 13th. The shares were sold at an average price of $71.51, for a total transaction of $84,739.35. Following the completion of the sale, the insider owned 65,947 shares in the company, valued at $4,715,869.97. The trade was a 1.77% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Jason Adair sold 688 shares of the stock in a transaction on Monday, July 27th. The stock was sold at an average price of $87.53, for a total transaction of $60,220.64. Following the sale, the insider directly owned 216,438 shares in the company, valued at $18,944,818.14. This trade represents a 0.32% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last 90 days, insiders sold 1,756,861 shares of company stock worth $122,981,112. 25.60% of the stock is owned by insiders.

Institutional Investors Weigh In On Liquidia

A number of institutional investors have recently modified their holdings of LQDA. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in Liquidia by 4.7% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 37,681 shares of the company’s stock worth $556,000 after acquiring an additional 1,700 shares during the last quarter. Goldman Sachs Group Inc. grew its holdings in shares of Liquidia by 10.7% during the first quarter. Goldman Sachs Group Inc. now owns 861,231 shares of the company’s stock valued at $12,703,000 after purchasing an additional 82,955 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in shares of Liquidia by 15.2% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 121,756 shares of the company’s stock worth $1,796,000 after purchasing an additional 16,022 shares during the period. Creative Planning lifted its holdings in shares of Liquidia by 40.7% in the 2nd quarter. Creative Planning now owns 26,840 shares of the company’s stock worth $334,000 after purchasing an additional 7,765 shares during the last quarter. Finally, Legal & General Group Plc boosted its position in Liquidia by 13.4% during the 2nd quarter. Legal & General Group Plc now owns 94,152 shares of the company’s stock valued at $1,174,000 after purchasing an additional 11,111 shares during the period. Institutional investors own 64.54% of the company’s stock.

Liquidia News Summary

Here are the key news stories impacting Liquidia this week:

• Positive Sentiment: YUTREPIA sales drove second-quarter revenue to $171.68 million, exceeding the $168.48 million consensus estimate, while revenue increased more than 1,800% year over year. Management also highlighted rising demand for the inhaled lung-disease treatment. LQDA Q2 Earnings Top
• Positive Sentiment: Liquidia is targeting more than $1 billion in 2027 net revenue as YUTREPIA gains market share and helps fund a broader inhaled-treprostinil pipeline, providing investors with a significant long-term growth narrative. LQDA Earnings Call Highlights
• Positive Sentiment: Bank of America raised its price target from $79 to $92, while BTIG Research and Needham indicated further appreciation potential. These targets support the bullish case, although Bank of America retained a neutral rating. Bank of America Price Target
• Neutral Sentiment: Lifesci Capital initiated or maintained a Market Perform view, reflecting more balanced expectations despite the company’s strong commercial momentum. Lifesci Capital Rating
• Negative Sentiment: Second-quarter adjusted earnings of $0.74 per share narrowly missed the $0.76 consensus estimate. The results triggered a negative reaction despite the revenue beat, particularly after LQDA had already risen sharply this year. Liquidia Shares Gap Down
• Negative Sentiment: HC Wainwright lowered its third-quarter 2026 EPS forecast to $1.01 from $1.15, adding pressure to near-term expectations. With a reported price-to-earnings ratio above 54, investors may be particularly sensitive to estimate reductions. HC Wainwright Estimate Revision

About Liquidia

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).